Pro Forma Financials Reveal Nearly 1900% Dilution from Preferred Stock Conversion

summarizeSummary

Sensei Biotherapeutics filed pro forma financials quantifying a nearly 1900% dilution from the upcoming conversion of Series B Preferred Stock, a critical step in its recapitalization plan following an acquisition and $200 million private placement.

check_boxKey Events · Financing and Capital Events · SNSE

• Massive Dilution Quantified

  Unaudited pro forma financials show weighted-average shares outstanding will increase by nearly 1900% (from approximately 1.3 million to 25.7 million) upon the conversion of Series B Preferred Stock.

• Shareholder Vote Pending

  The conversion of Series B Preferred Stock is contingent on shareholder approval at the annual meeting scheduled for June 10, 2026.

• Recapitalization Context

  This conversion is part of the previously announced acquisition of Faeth Therapeutics and a $200 million private placement, which were undertaken to address the company's prior "going concern" warning.

• Discounted PIPE Pricing

  The private placement shares were priced at $13.85 on an as-converted basis, representing a significant discount compared to the current stock price of $17.56.

auto_awesomeAnalysis · SNSE · Life Sciences

This 8-K, filed concurrently with a proxy supplement, provides unaudited pro forma financial information detailing the massive dilution expected from the conversion of Series B Preferred Stock. This conversion, subject to shareholder approval on June 10, 2026, will increase the weighted-average shares outstanding by nearly 1900%, from approximately 1.3 million to 25.7 million. This recapitalization stems from the recent acquisition of Faeth Therapeutics and a $200 million private placement, which were critical for the company's survival given its prior "going concern" warning. While securing capital, the extreme dilution significantly impacts existing shareholder value.